Salubris' innovative drugs Allisartan and Enarodustat® were enrolled into 2023 National Reimbursement Drug List(NRDL)

Publisher: Views:

Good news

On December 13, 2023, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2023). Salubris' innovative drug for renal anemia, Enarodustat恩那罗 ® (Enarodustat Tablets), was officially included in the latest NRDL, and the Class 1 anti-hypertension drug Allisartan (Allisartan Isoproxil tablets) was also successfully renewed through negotiation.


· Enarodustat恩那罗 ®Enarodustat Tablets

Enarodustat, for the treatment of anemia in non-dialysis adult patients with chronic kidney disease (CKD), is a new generation of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drug marketed in China. After being listed in the NRDL, Enarodustat will provide patients with new medication options and more patients can access to this drug.

· Allisartan (Allisartan Isoproxil tablets)

Allisartan, for the treatment of mild and moderate primary hypertension, is the only angiotensin II receptor antagonist that is independently developed in China with independent intellectual property rights (class 1.1 drugs). Since its launch, a number of clinical studies in the field of hypertension have been carried out to provide more evidence-based medical evidence for market promotion.

In 2017, Allisarta was included in the "Negotiated Drugs of the Agreement Period" of the NRDL for the first time, and according to the relevant rules, after the expiration of this agreement, Allisarta will be included in the Category B of National Drug Catalogue, and the current payment standards will be temporarily implemented without further negotiation.

1. Enandostat tablet label

2. Allisartan Isoproxil tablets label


In the future, Salubris will continue to adhere to the mission of "patient-centered", focus on the research and development of innovative drugs to meet unmet clinical needs in the field of chronic diseases, and improve the health and well-being of patients with scientific and technological innovation.